Humanized antibodies that recognize alpha-synuclein

Patent metadata

Field	Value
Publication number	US-9234031-B2
Application number	US-201414340342-A
Country	US
Kind code	B2
Filing date	Jul 24, 2014
Priority date	Jan 27, 2012
Publication date	Jan 12, 2016
Grant date	Jan 12, 2016

Abstract

The present application discloses humanized 1H7 antibodies. The antibodies bind to human alpha synuclein and can be used for treatment and diagnosis of Lewy body disease.

First claim

What is claimed is:

1. A nucleic acid encoding a mature heavy chain variable region and/or a mature light chain variable region of an antibody comprising a mature heavy chain variable region, wherein position H97 by Kabat numbering is C, M, S or T and other residues of the three Kabat CDRs are as defined by SEQ ID NO:44, and the heavy chain variable region is at least 90% identical to SEQ ID NO:44, and a mature light chain variable region comprising the three Kabat CDRs of SEQ ID NO:45, and being at least 90% identical to SEQ ID NO:45, wherein the antibody specifically binds to human alpha synuclein.

2. The nucleic acid of claim 1 , wherein the amino acid sequence of the mature heavy chain variable region is SEQ ID NO:44 and the amino acid sequence of the mature light chain variable region is SEQ ID NO:45 except provided that position L46 (Kabat numbering) is occupied by L or F, and/or position L49 (Kabat numbering) is occupied by Y or C, and/or position L83 (Kabat numbering) is occupied by F or A, and/or position H11 (Kabat numbering) is occupied by V or L, and/or position H28 (Kabat numbering) is occupied by T or S, and/or position H38 (Kabat numbering) is occupied by R or K, and/or position H48 (Kabat numbering) is occupied by M or I, and/or position H67 (Kabat numbering) is occupied by V or A, and/or position H69 (Kabat numbering) is occupied by M or L, and/or position H71 (Kabat numbering) is occupied by T or A, and/or position H91 (Kabat numbering) is occupied by Y or F, and/or H97; (Kabat numbering) is occupied by C or S, and wherein the antibody specifically binds to human alpha synuclein.

3. The nucleic acid of claim 1 , having a heavy chain sequence comprising SEQ ID NO:22 and/or a light chain sequence comprising SEQ ID NO:36.

4. The nucleic acid of claim 1 , having a heavy chain sequence comprising SEQ ID NO:22 and a light chain sequence comprising SEQ ID NO:36.

5. The nucleic acid of claim 1 , wherein the mature heavy chain variable region has an amino acid sequence designated SEQ ID NO:23 and the mature light chain variable region has an amino acid sequence designated SEQ ID NO:37.

6. The nucleic acid of claim 5 , wherein the mature heavy chain variable region is fused to a heavy chain constant region having the amino acid sequence designated SEQ ID NO:52, wherein the C-terminal lysine residue is optionally omitted and the mature light chain constant region is fused to a light chain constant region having the amino acid sequence designated SEQ ID NO:49.

7. The nucleic acid of claim 1 having a sequence comprising any one of SEQ ID NO: 18, 20, 22, 24, 26, 32, 34, 36, or 38.

8. A host cell comprising a vector comprising the nucleic acid of claim 1 or 7 .

9. A method of producing an antibody, comprising culturing cells transformed with nucleic acids encoding the heavy and light chains of the antibody, so that the cells secrete the antibody; and purifying the antibody from cell culture media; wherein the antibody is defined by claim 1 or 7 .

Assignees

• Prothena Biosciences Ltd

Inventors

• Saldanha Jose
• Nijjar Tarlochan S

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P25/16

  Anti-Parkinson drugs · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title